Novo Nordisk A/S
· NVO
281 B
-2.69%
Growth
· FY
Rev. 1Y%
25.03%
RPS 3Y CAGR
28.60%
RPS 10Y CAGR
14.47%
EPS 1Y%
142.85%
EPS 3Y CAGR
29.68%
EPS 10Y CAGR
16.24%
Profitability
· FY
Gross Margin
84.33%
Op. Inc. Margin
44.53%
Profit Margin
34.51%
ROE
81.24%
ROA
21.39%
ROCE
53.34%
$0
281.47 B
18.10
4.89
1.92
6.21
25.19
Competitive Advantages
1
Market Leadership in Diabetes Care: NVO is the global market leader in diabetes care, with a strong portfolio of insulins, antidiabetic drugs, and diabetes management devices.
2
Strong Research and Development: NVO invests heavily in R&D, driving innovation in diabetes treatment and management.
Risks
1
Patent Expiration: Loss of exclusivity for key blockbuster drugs
2
Competition: Intense competition from both generic and branded rivals
Fundamental Charts
Revenue by Geography
Subscribe to unlock chart
Try Premium free for 7 days
Operating Income by Segment
Subscribe to unlock chart
Try Premium free for 7 days